DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20211786

A case of mistaken identity: an enthesitis-related arthritis case report

Michael F. Blackard, Prapti A. Patel, Divya A. Pandya, Manish K. Gupta, Abhijit S. Pandya

Abstract


Juvenile idiopathic arthritis is the most common inflammatory rheumatological condition affecting children. The condition stems from the inability of the immune system to discriminate between self and not-self leading to inappropriate immune reactions against joints. The different subtypes are differentiated by the number of joints involved and the presence or absence of certain exclusion factors. Due to overlapping diagnostic criterion and range of clinical presentation, diagnosis can be a difficult task. Our patient initially presented with joint swelling without pain that was initially diagnosed with traumatic swelling that later was considered to be of an infectious etiology. A biopsy revealed synovitis but current treatment for traumatic and infectious causes continued to fail. Finally, an additional joint showed inflammation leading to additional testing that uncovered that the patient was positive for HLA-B27 as well as a first degree relative with ankylosing spondylitis. This coupled with the inflammatory biopsy findings led to the diagnosis of juvenile idiopathic arthritis. The identification of an HLA-B27 positive patient is important as this population has been shown to have low rates of remission, resistance to certain treatments used for juvenile idiopathic arthritis, specifically DMARDS and corticosteroids which are often first line treatments for juvenile idiopathic arthritis. The HLA-B27 patient population has also been shown to progress to axial involvement and joint destruction leading to earlier need for arthroplasties. As early identification is important in the determination to begin biologic treatments early in the disease course, physician should maintain a clinical suspicion for JIA when dealing with swollen joints in the pediatric population.


Keywords


Juvenile idiopathic arthritis, Rheumatoid factor, HLA B27, Pediatric, Auto inflammatory

Full Text:

PDF

References


Ringold S, Angeles-Han ST, Beukelman T. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res. 2019;71(6):717-734.

Qian X, Liu Y-X, Ye X. Gut microbiota in children with juvenile idiopathic arthritis: characteristics, biomarker identification, and usefulness in clinical prediction. BMC Genomics. 2020;21(1):286.

Petty RE, Southwood TR, Manners P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.

Weiss PF, Colbert RA. Juvenile Spondyloarthritis: A Distinct Form of Juvenile Arthritis. Pediatr Clin North Am. 2018;65(4):675-690.

Maniscalco V, Marrani E, Lamot L, Lionetti P, Simonini G. The conundrum of juvenile spondyloarthritis classification: Many names for a single disease? Lesson learned from an instructive clinical case. Int J Rheum Dis. 2020;23(9):1248-1251.

Nigrovic PA, Raychaudhuri S, Thompson SD. Review: Genetics and the Classification of Arthritis in Adults and Children. Arthritis Rheumatol. 2018;70(1):7-17.

Martini A, Ravelli A, Avcin T. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190-7.

Mahmud SA, Binstadt BA. Autoantibodies in the pathogenesis, diagnosis, and prognosis of juvenile idiopathic arthritis. Front Immunol. 2019;9.

Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017;29(5).

Hersh AO, Prahalad S. Genetics of Juvenile Idiopathic Arthritis. Rheum Dis Clin North Am. 2017;43(3):435-48.

Assadi G, Saleh R, Hadizadeh F. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Genes Immun. 2016;17(4):261-4.

Tejesvi M V, Arvonen M, Kangas SM. Faecal microbiome in new-onset juvenile idiopathic arthritis. Eur J Clin Microbiol Infect Dis. 2016;35(3):363-70.

Ferguson ID, Griffin P, Michel JJ. T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis. Front Immunol. 2018;9:1802.

Zahran AM, Abdallah AM, Saad K. Peripheral Blood B and T Cell Profiles in Children with Active Juvenile Idiopathic Arthritis. Arch Immunol Ther Exp (Warsz). 2019;67(6):427-32.

Nijhuis L, Peeters JGC, Vastert SJ, van Loosdregt J. Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis. Front Immunol. 2019;10:151.

Lamot L, Borovecki F, Tambic Bukovac L. Aberrant Expression of Shared Master-Key Genes Contributes to the Immunopathogenesis in Patients with Juvenile Spondyloarthritis. PLoS One. 2014;9(12):e115416.

Perica M, Vidović M, Lamot L. Erratum to: Single nucleotide polymorphism of toll-like receptor 4 (TLR4) is associated with juvenile spondyloarthritis in Croatian population. Clin Rheumatol. 2015;34(12):2087.

Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am. 2018;65(4):657-74.

Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017;34(2):90-101.

Żuber Z, Turowska-Heydel D, Sobczyk M, Chudek J. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia. 2015;53(3):125-30.

Goirand M, Breton S, Chevallier F. Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol Online J. 2018;16(1):21.

Savolainen HA, Lehtimäki M, Kautiainen H, Aho K, Anttila P. HLA B27: a prognostic factor in juvenile chronic arthritis. Clin Rheumatol. 1998;17(2):121-4.

Berntson L, Nordal E, Aalto K. HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis. J Rheumatol. 2013;40(5):725-731.

Hsu C-T, Lin Y-T, Yang Y-H, Chiang B-L. Factors affecting clinical and therapeutic outcomes of patients with juvenile rheumatoid arthritis. Scand J Rheumatol. 2004;33(5):312-317.

Bava C, Mongelli F, Pistorio A. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2019;17(1):50.

Gmuca S, Xiao R, Brandon TG. Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthritis Res Ther. 2017;19(1):84.

Weiss PF, Xiao R, Brandon TG. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol. 2018;45(1):107-14.